Side-by-side · Research reference

ARA 290vsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED17/59 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

ARA 290

EPO-Derived Peptide · Innate Repair Receptor Agonist

4 mgDaily doseBrines 2015 Culver 2017

28 daysPhase 2 durationCulver 2017

Non-erythropoieticSafety profileBrines 2015 Liu 2014

SQ · DailyBrines 2015 Culver 2017

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

ARA 290

Thymalin

Primary target

Innate repair receptor (EPO receptor / CD131 heterodimer)

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014 Culver 2017

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

N/A — does not interact with hematopoietic EPO receptorLiu 2014

—

Origin

11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

Not reported in clinical trials

—

02Dosage Protocols

Parameter

ARA 290

Thymalin

Standard dose (Phase 2)

4 mg / dayBrines 2015 Culver 2017

Sarcoidosis SFN and diabetic neuropathy trials.

—

Frequency

Once daily

Self-administered subcutaneously.

Once daily during cycle

Duration

28 days (Phase 2)Culver 2017

Corneal nerve improvements observed by day 28.

5–10 day cycles, 1–2× per year

Evidence basis

Phase 2 RCTsCulver 2017 Brines 2015

64-subject sarcoidosis trial, type 2 diabetes trial.

Russian clinical + in vitroKhavinson 2002

Route

SubcutaneousBrines 2015

—

Timing

Any time of day

No circadian dependence reported.

Morning preferred

Standard dose

—

5–10 mg / day IM × 5–10 daysKhavinson 2002

Lower / starter dose

—

2.5 mg / day

Reconstitution

—

Saline or bacteriostatic water

Half-life

—

Hours (estimated)

03Metabolic / Fat Loss Evidence

Parameter

ARA 290

Thymalin

Primary effect

Improved metabolic control (HbA1c, fasting glucose)Brines 2015

Secondary to neuropathy treatment; direct lipolytic effects not established.

—

HbA1c

Significant reduction vs placebo

Observed in type 2 diabetes + neuropathy trial.

—

Fasting glucose

Improved in ARA 290 group

—

Body composition

Not directly quantified

Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.

—

04Side Effects & Safety

Parameter

ARA 290

Thymalin

Injection site reaction

Mild, transient

Mild erythema at IM site

Hematopoiesis

None — non-erythropoietic

Distinguishes ARA 290 from native EPO.

—

Cardiovascular

No thrombotic events or hypertension reported

—

Immunogenicity

No antibody formation reported

—

Tolerability

Well-tolerated in Phase 2 trialsCulver 2017 Brines 2015

—

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

ARA 290

·Hypersensitivity to ARA 290

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

ARA 290

·Active malignancy (theoretical EPO-axis concern; not observed in trials)

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

ARA 290

Thymalin

1. Preparation

Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015

Morning preferred during cycle.

4. Dosing

4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Storage

Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.

23–25G, 25–38 mm IM needle.

06Stack Synergy

ARA 290

+ BPC-157

Moderate

View BPC-157 →

ARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.

ARA 290: 4 mg SQ · daily
BPC-157: 250–500 mcg SQ · daily
Frequency: Once daily, same or separate injections
Primary benefit: Nerve regeneration, pain reduction, tissue healing

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001